干扰素α-1b联合胸腺因子D治疗慢性乙型肝炎的临床观察  

A clinical observation on interferon α-1b combined with TFD in the treatment of chronic hepatitis B.

作　　者：占国清[1] 郑三菊[1] 邓文钦[1] 李金科[1] 

机构地区：[1]郧阳医学院附属人民医院肝病研究室,湖北十堰442000

出　　处：《临床肝胆病杂志》2004年第3期163-164,共2页Journal of Clinical Hepatology

摘　　要：探讨干扰素α- 1b联合胸腺因子D(TFD)治疗慢性乙型肝炎 (CHB)的疗效。 12 0例CHB患者随机分为干扰素α- 1b联合胸腺因子D、干扰素α - 1b及胸腺因子D三组 ,观察各组的ALT、乙肝病毒标志物 (HBVM)及HBVDNA的变化。结果显示治疗结束联合组和干扰素组ALT的复常率、HBVDNA转阴率、HBeAg阴转率及抗 -HBe阳转率均明显高于胸腺因子D组 (P <0 0 1)。联合组较干扰素α - 1b组更有效治疗慢性乙型肝炎 ,但它们之间的差异无显著性 (P >0 0 5 )。随访 6月 ,联合组和干扰素组的上述指标仍高于胸腺因子D组 (P <0 0 5 ) ,且联合组HBVDNA阳转反跳率低于干扰素α- 1b组 (P <0 0 5 )。说明干扰素α - 1b联合胸腺因子D治疗CHB患者有较好的效果。To investigative the clinical efficacy of interferon combined with Thymic Factor D (TFD) in the treatment of chronic hepatitis B. 120 patients with chronic hepatitis B were randomly divided into IFNα-lb with TFD, IFNα-lb, and TFD groups to observe ALT, HBV DNA and viral marker changes. At the end of treatment, the rate of normal ALT, the negative rate of HBV DNA and HBeAg, and the positive rate of HBeAb were higher in IFNα-lb with TFD and IFNα-lb groups than TFD group (P<0.01). There was no obvious significant different between IFNα-lb with TFD and IFNα-lb groups (P<0.05). After 6 months follow up, those were still higher in IFNα-lb with TFD and IFNα-lb groups than TFD group, but the positive rate of HBV DNA is higher in IFNα-lb than the combination group (P<0.05). The IFNα-1b combined with TFD is efficient to treat patients with chronic hepatitis B.

关 键 词：干扰素Α-1B 联合用药 胸腺因子D 药物治疗 慢性乙型肝炎 

分 类 号：R512.62[医药卫生—内科学]